<DOC>
	<DOC>NCT00326469</DOC>
	<brief_summary>To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of lanreotide Autogel in tumour growth stabilization.</brief_summary>
	<brief_title>Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>patients with histopathologic diagnosis of welldifferentiated neuroendocrine tumour or carcinoma according to WHO classification patients who, according to RECIST criteria (Response Evaluation Criteria in Solid Tumours) present measurable disease patients with progressive disease in the previous 6 months before their inclusion in the study patients with positive IN111 octreotide scintigraphy patients with surgically removable localised disease patients with progressive disease in the first six months of being diagnosed patients with intestinal obstruction due to a carcinoid tumour patients who have received treatment with somatostatin analogues during the 6 months before being included in the study patients who have received treatment with radiotherapy, chemotherapy or interferon 4 weeks before being included in the study, or planned to receive these during the study patients who have received treatment with liver artery embolisation or radiopharmaceuticals (endoradiotherapy) 12 weeks before being included in the study, or planned during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>